Dispute Arises Over Hospital-Acquired Infection Tests
This article was originally published in The Gray Sheet
Executive Summary
French diagnostic firm BioMérieux is attempting to renege on a licensing agreement with Becton Dickinson relating to methods for detecting one of the most common infections picked up in hospitals, according to BD
You may also be interested in...
BD hospital infection settlement
Becton Dickinson and French diagnostics firm BioMérieux settle an arbitration dispute initiated by BioMérieux in April to terminate an agreement granting detection method rights for methicillin resistant Staphylococcus aureus, a common hospital-acquired infection, to BD subsidiary GeneOhm Sciences, BD notes in an Aug. 8 Securities and Exchange Commission filing. BD/GeneOhm retains access to use the technology under the settlement (1"The Gray Sheet" April 30, 2007, p. 9)...
BD hospital infection settlement
Becton Dickinson and French diagnostics firm BioMérieux settle an arbitration dispute initiated by BioMérieux in April to terminate an agreement granting detection method rights for methicillin resistant Staphylococcus aureus, a common hospital-acquired infection, to BD subsidiary GeneOhm Sciences, BD notes in an Aug. 8 Securities and Exchange Commission filing. BD/GeneOhm retains access to use the technology under the settlement (1"The Gray Sheet" April 30, 2007, p. 9)...
BD Targets Hospital-Associated Infections With $230 Mil. Acquisition
BD's acquisition of molecular diagnostic firm GeneOhm Sciences enters the medical technology company into the purportedly $500 mil.-plus healthcare-associated infections market